NGEN Stock Forecast & Price Target

NervGen Pharma is attractive because its lead asset NVG-291 has already shown proof-of-concept in cervical incomplete SCI, with 2.6x greater mean GRASSP Total Score improvement than placebo at week 16, 3.7x greater improvement in grasping, and durable gains in bladder control, spasticity, and motor signaling. The recent underwritten public offering of 24M shares and warrants generated $60M of gross proceeds, which should be sufficient to fund the RESTORE program and preserve optionality for a future U.S. launch if warrants are exercised. Its differentiated CSPG-inhibition mechanism, broad IP estate, and a large unmet SCI market of ~147,000 prevalent U.S. patients and ~9,000 new cases annually support the view that the company can build meaningful long-term value if the anticipated pivotal program validates these early clinical signals.

NervGen Pharma is a high-risk clinical-stage biotech whose value depends heavily on NVG-291, yet the company still faces major binary events from the RESTORE Phase 3 trial through regulatory submission and approval. Its financial profile is weak, with forecast diluted net losses of CAN$0.49 per share in 2026 and CAN$0.67 per share in 2027, only $22.1 million in cash at end-2025, and the possibility of additional capital needs to finish pivotal development. The stock also carries substantial execution risk from a 45% probability of approval assumption, potential equity dilution, slow sales uptake, and competition from better-resourced firms such as Mitsubishi Tanabe Pharma and AbbVie, while profitability may not arrive until 2030 at the earliest.